NCT05638282View on ClinicalTrials.gov

A Study to Evaluate the Safety and Tolerability of Cendakimab in Chinese Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 15, 2023

Primary Completion Date

June 27, 2023

Study Completion Date

June 27, 2023

Conditions
Healthy Participants
Interventions
DRUG

Cendakimab

Specified dose on specified days

DRUG

Placebo

Specified dose on specified days

Trial Locations (1)

510080

Local Institution - 0001, Guangzhou

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05638282 - A Study to Evaluate the Safety and Tolerability of Cendakimab in Chinese Healthy Participants | Biotech Hunter | Biotech Hunter